Repligen Corporation
Repligen Corporation (RGEN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rgen · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Repligen Corporation (RGEN) measures how much investors pay for each dollar of the company's trailing earnings. RGEN's current PE ratio of 138.06x is calculated by dividing its stock price of $125.47 by its TTM earnings per share of $0.91. −13.9% discount vs 5Y avg 160.4x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 16 fiscal years · Front-end computedMinQ1 · 25%94.1x
MedianQ3 · 75%281.4x
Max
At 138.06x, RGEN's current P/E is within its average historical range over the past 16 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Repligen CorporationYou RGEN | $7.1B | 138.06x | +833.2% | $0.91 |
 AptarGroup, Inc. ATR | $7.1B | 20.41x | +38.0% | $5.97 |
 Avantor, Inc. AVTR | $6.7B | N/A | — | -$0.78 |
 Baxter International Inc. BAX | $10.0B | N/A | — | -$1.87 |
 Bio-Rad Laboratories, Inc. BIO | $8.0B | 10.87x | -26.5% | $27.87 |
 Charles River Laboratories International, Inc. CRL | $8.9B | N/A | — | -$2.91 |
 DaVita Inc. DVA | $12.2B | 13.10x | -11.5% | $8.67 |
Industry Average 3 peers with valid PE | — | 14.79x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 188.46x | $0.87 | — | |
2024-12-31 FY2024 | — | $-0.46 | — | |
2023-12-31 FY2023 | 281.45x | $0.64 | +457.4% | |
2022-12-31 FY2022 | 50.49x | $3.35 | -55.5% | |
2021-12-31 FY2021 | 113.57x | $2.33 | -32.4% | |
2020-12-31 FY2020 | 168.06x | $1.14 | -19.5% | |
2019-12-31 FY2019 | 208.85x | $0.44 | +50.4% | |
2018-12-31 FY2018 | 138.91x | $0.38 | +183.9% | |
2017-12-31 FY2017 | 48.92x | $0.74 | -44.8% | |
2016-12-31 FY2016 | 88.58x | $0.35 | -11.0% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Repligen Corporation (RGEN) measures how much investors pay for each dollar of the company's trailing earnings. RGEN's current PE ratio of 138.06x is calculated by dividing its stock price of $125.47 by its TTM earnings per share of $0.91.
Frequently asked questions
RGEN pe ratio · 6 questionsRGEN's current PE ratio is 138.06x as of 2026-06-08, based on a stock price of $125.47 and TTM EPS of $0.91. Data sourced from Financial Modeling Prep via RGEN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Repligen Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08